Skip to main content
. 2017 Nov 27;12(11):e0188120. doi: 10.1371/journal.pone.0188120

Table 2. Overall lifetime cancer prevalence and specific subtypes of cancer prevalence in patients with MS (n = 1107) and controls (n = 1568).

Patients with MS
% (n)		 Controls
% (n)
Patients with history of cancer 7.32 (81 patients, 84 cancers) 12.63 (198 patients, 214 cancers)
Breast cancers 2.53 (28) 2.42 (38)
Skin cancers
    ▪ Basal-cell carcinomas
    ▪ Squamous-cell carcinomas
    ▪ Melanomas
    ▪ Others skin cancers 		1.36 (15)
▪ 0.90 (10)
▪ 0.00 (0)
▪ 0.36 (4)
▪ 0.09 (1)
 2.04 (32)
▪ 1.21 (19)
▪ 0.06 (1)
▪ 0.64 (10)
▪ 0.13 (2)
Urological cancers
    ▪ Prostatic cancers
    ▪ Renal cancers
    ▪ Bladder cancers
    ▪ Testicular cancers 		0.72 (8)
▪ 0.27 (3)
▪ 0.36 (4)
▪ 0.09 (1)
▪ 0.00 (0)		 2.93 (46)
▪ 1.98 (31)
▪ 0.57 (9)
▪ 0.32 (5)
▪ 0.06 (1)
Gynecological cancers other than breast
    ▪ Ovarian cancers
    ▪ Uterine cancers (cervical or endometrial)
 1.17 (13)
▪ 0.09 (1)
▪ 1.08 (12)		 1.79 (28)
▪ 0.45 (7)
▪ 1.34 (21)
Gastro-intestinal cancers
    ▪ Colorectal cancers
    ▪ Oesophageal cancers
    ▪ Gastric cancers
    ▪ Others GI cancers 		0.90 (10)
▪ 0.81 (9)
▪ 0.00 (0)
▪ 0.09 (1)
▪ 0.00 (0)
 1.53 (24)
▪ 1.28 (20)
▪ 0.06 (1)
▪ 0.00 (0)
▪ 0.19 (3)
Brain tumors 0.00 (0) 0.13 (2)
Thyroid cancers 0.36 (4) 0.57 (9)
Hemopathies 0.36 (4) 1.02 (16)
Naso-pharyngeal cancers 0.18 (2) 0.57 (9)
Bronchopulmonary cancers 0.00 (0) 0.64 (10)